Abscopal Effects Induced by Radiotherapy Combined with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Recurrent or Refractory Metastatic Thymic Epithelial Tumors: A Single-Institution Experience

J. Wen,J. Chen,X. Xu,D. Liu,Y. Gu,J. Zhang,M. Fan

DOI: https://doi.org/10.1016/j.ijrobp.2020.07.1279

2020-01-01

Abstract:The abscopal effect is defined as tumor regression seen at sites distant from the irradiated tissue. We aimed to observe the abscopal effects in patients diagnosed with recurrent or refractory advanced thymic epithelial tumors by treating with granulocyte-macrophage colony-stimulating factor (GM-CSF) and radiotherapy. In this retrospective serial, thymic epithelial tumor patients with at least three distinct measurable sites of disease, treated with concurrent radiotherapy (35 Gy in ten fractions or 30 Gy in ten fractions, over 2 weeks) to one metastatic site and GM-CSF (125 μg/m2 subcutaneously injected daily for 2 weeks, starting during the second week of radiotherapy), were recruited. The course was repeated, targeting a second metastatic site. No systemic treatment was applied. The primary endpoint was the proportion of patients with an abscopal response (estimated using investigator-assessed Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1) and the secondary endpoint was toxicity and progression free survival (PFS). From April 12, 2016, to Sep 9, 2019, 12 patients were enrolled. One patient was excluded because of histologically confirmed with small cell malignant tumor. Another thymic carcinoma patient who developed heart injury during treatment and did not complete scheduled therapy was then only evaluable for toxicity. Among ten patients who were eligible for efficacy evaluation, there were three with thymic squamous cell carcinoma, one with type B1, three with type B2 and three with type B3 thymoma, respectively. Four patients had Masaoka-Koga stage IVa diseases and six had stage IVb diseases. The median follow-up time was 17 months (Interquartile Range = 10, 23). The abscopal response was observed in 3 out of 10 patients (30%) with 2 partial responses (one thymic carcinoma and one type B1 thymoma) and 1 complete response (type B3 thymoma). Five patients with malignant thymoma were assessed as stable disease as their best response. Two patients with thymic carcinoma suffered from disease progression. The median PFS was 25 months for abscopal responders. 1-year PFS rate was 100% for abscopal responders while the value was 55.6% for non-responders (p = 0.21). Four patients had grade 3 adverse events (heart injury, anemia, leucopenia and neutropenia). The most common grade 2 adverse events were leucopenia (three patients). Myasthenia gravis (grade 2) was observed in one patient. The combination GM-CSF and local radiotherapy alone generated clear abscopal effects in patients with recurrent or refractory advanced thymic epithelial tumors.